Pythium insidiosum-antigen (PIA) immunotherapy has been used to treat human pythiosis. This study compared PIA-stimulated and unstimulated neutrophils on zoospore viability of P. insidiosum strains. We cultured and collected zoospores of 6 P. insidiosum strains, CBS 777.84, ATCC 58643, ATCC 90586, PEC1, PC10, and CBS 101039. PIA concentrations of 0.01, 0.1, 1, and 10 µg/ml were prepared and were used to stimulate neutrophils isolated from healthy volunteers. The MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay was used to calculate the zoospore viability of P. insidiosum strains. Neutrophils stimulated with 0.01 or 0.1 µg/ml PIA, or both, showed a significant reduction in the viability of zoospores of CBS 777.84, ATCC 58643, CBS 101039, PC10, and PEC1 strains. Furthermore, 1 µg/ml PIA-induced neutrophils elicited a significant decrease in the viability of zoospores of ATCC 58643, CBS 101039, and PC10 strains. However, a higher dose of PIA (10 µg/ml) did not demonstrate superiority in reducing the zoospore viability of all six strains. Our findings suggest that PIA immunotherapy improves the zoospore-killing activity of neutrophils, and neutrophils might be involved in the forefront mechanism responsible for the beneficial effects of PIA immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822016 | PMC |
| http://dx.doi.org/10.1038/s41598-025-88962-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pythium insidiosum-antigen enhances neutrophil-mediated killing of zoospores.
Sci Rep
February 2025
Department of Transfusion Medicine and Clinical Microbiology, Faculty of Allied Health Sciences, Chulalongkorn University, 154 Soi Chula12, Phayathai Road, Pathumwan, Bangkok, 10330, Thailand.
Pythium insidiosum-antigen (PIA) immunotherapy has been used to treat human pythiosis. This study compared PIA-stimulated and unstimulated neutrophils on zoospore viability of P. insidiosum strains.
View Article and Find Full Text PDFAre psychological attitudes towards vaccination an expression of personality? A cross-sectional study on COVID-19 vaccination in France.
BMC Public Health
January 2025
Emerging Diseases Epidemiology Unit, Institut Pasteur, 25-28 Rue du Docteur Roux, Bâtiment Laveran, Paris, 75015, France.
Background: The capacity of the 7C model's psychological antecedents, which include confidence in vaccines, complacency, convenience, calculation, collective responsibility, confidence in the wider system, and social conformism, to explain variance in COVID-19 vaccine intentions and behaviours has been documented. However, it remains unclear whether the attitudes represented by the 7C psychological antecedents are specific to vaccination or if they are, in fact, an expression of underlying personality traits.
Methods: From February to June 2022, French adults completed self-administered questionnaires assessing COVID-19 vaccination history, the 7C antecedents, and personality traits ("ComCor" and "Cognitiv" studies).
Antigen affinity and site of immunization dictate B cell recall responses.
Cell Rep
January 2025
Department of Microbiology, Tumor and Cell Biology, Division of Virology and Immunology, Karolinska Institutet, 171 65 Solna, Sweden. Electronic address:
Protective antibodies against HIV-1 require unusually high levels of somatic mutations introduced in germinal centers (GCs). To achieve this, a sequential vaccination approach was proposed. Using HIV-1 antibody knockin mice with fate-mapping genes, we examined if antigen affinity affects the outcome of B cell recall responses.
View Article and Find Full Text PDFSafety and Tolerability of Home Infusions in Down Syndrome Regression Disorder.
Clin Ther
February 2025
Division of Neuroimmunology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California; Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, California.
Purpose: Down syndrome regression disorder (DSRD) is a rare neuropsychiatric condition affecting otherwise healthy individuals with Down syndrome. Multiple studies on DSRD have revealed that immunotherapy with intravenous immunoglobulin (IVIg) is both safe and effective, although site of infusion has never been studied. This study sought to evaluate the safety and tolerability of IVIg in individuals with DSRD receiving home-based infusions.
View Article and Find Full Text PDFPD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation - therapeutic implications for autoimmunity.
J Autoimmun
December 2024
Immunology Discovery Research, Lilly Research Laboratories, Lilly Biotechnology Center, San Diego, CA, USA. Electronic address:
PD-1 has emerged as a central inhibitory checkpoint receptor in maintaining immune homeostasis and as a target in cancer immunotherapies. However, targeting PD-1 for the treatment of autoimmune diseases has been more challenging. We recently showed in a phase 2a trial that PD-1 could be stimulated with the PD-1 agonist antibody peresolimab to treat rheumatoid arthritis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!